Roberts, Glore & Co’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
DAM
F
Roberts, Glore & Co's NVO Position: Q1 2026 in Review
Roberts, Glore & Co increased its Novo Nordisk (NVO) stake by 40% in Q1 2026, buying an estimated $491K and bringing the position to 36,518 shares worth $1.34M. The position accounts for 0.37% of the portfolio, ranked #67.
Roberts, Glore & Co first reported a position in NVO in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.49M in Q3 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Roberts, Glore & Co held 36,518 shares of Novo Nordisk worth $1.34M as of Q1 2026.
- Roberts, Glore & Co bought 10,370 Novo Nordisk shares in Q1 2026, an estimated $491K.
- Novo Nordisk made up 0.37% of Roberts, Glore & Co's portfolio in Q1 2026, its #67 holding.
- Roberts, Glore & Co first reported a position in Novo Nordisk in Q2 2021 and has held it in 19 quarters since.
- Roberts, Glore & Co's Novo Nordisk position peaked at $1.49M in Q3 2025.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.